Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.
Journal Article (Journal Article)
PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy. Within, we report on the ongoing phase I study evaluating the intratumoral convection-enhanced delivery (CED) of PVSRIPO.
Full Text
Duke Authors
- Bigner, Darell Doty
- Desjardins, Annick
- Friedman, Allan Howard
- Friedman, Henry Seth
- Gromeier, Matthias
- Herndon II, James Emmett
- Peters, Katherine Barnett
- Sampson, John Howard
Cited Authors
- Desjardins, A; Sampson, JH; Peters, KB; Ranjan, T; Vlahovic, G; Threatt, S; Herndon, JE; Boulton, S; Lally-Goss, D; McSherry, F; Friedman, AH; Friedman, HS; Bigner, DD; Gromeier, M
Published Date
- July 2014
Published In
Volume / Issue
- 16 Suppl 3 /
Start / End Page
- iii43 -
PubMed ID
- 25165331
Pubmed Central ID
- PMC4144655
Electronic International Standard Serial Number (EISSN)
- 1523-5866
Digital Object Identifier (DOI)
- 10.1093/neuonc/nou209.5
Language
- eng
Conference Location
- England